Antwerp’s Sightera Biosciences raises €3 million to scale its patient-derived AI drug discovery platform | EU-Startups

Funding Rounds

▤ Summary

Sightera Biosciences raised €3 million in pre-seed funding led by Entourage, Anacura, and QBIC. The Antwerp-based startup builds an AI-native drug discovery platform that trains on proprietary patient-derived biological data rather than generic public datasets. It plans to use the capital to grow its team, expand its platform and preclinical portfolio, and advance its lead oncology program toward preclinical candidate selection. The company also aims to prepare a larger financing round to move SIGHT001 into clinical trials and eventually out-license assets to pharmaceutical partners.

$ Funding

$
Amount $3.3M Total raised
□
Date July 17, 2026 Announcement date
◎
Investors University of Antwerp Lead investors
▥
Company sightera-biosciences.com Funded company

▥ Classifications

industries
Fintech & Banking
applications
AI & Machine learning

◇ AskAI Classifications

Labels
Biotechnology Software as a Service (SaaS) Artificial Intelligence in Drug Discovery

▦ Linked Companies